Next, we investigated anti-WM activity of the Bcl-2-specific BH3 mimetic, venetoclax (ABT-199, recently Food and Drug Administration-approved for treatment of 17p deletion-positive relapsed/refractory CLL),37, 38, 39 in WT and ibrutinib-resistant derivatives. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.